Table Info

Table 2.

Anticancer effects of cardamonin in vivo

Cancers	Cell line	Phenotypic effects	Mechanisms of action	References
Breast cancer	MDA-MB-231	Inhibitory effects on tumor angiogenesis	↓Bcl-2, ↑Bax, ↑caspase-3, ↓HIF-1a, ↓LDHA	[36]
Breast cancer	Drug-resistant CSC’s	Inhibited tumor growth and volume	-	[37]
Gastric cancer	BCG-823/5-FU	Reduced tumor growth	-	[50]
Leukemia	BALB/c mice	-	↓CD3, ↓CD11b, ↓Mac-3, ↑CD19	[53]
Lung cancer	NSCLC A549, H460	Reduced cell proliferation and metastatic abilities	↓Ki-67, ↓mTOR, ↓Akt	[60]
Lung cancer	LLC cells	Suppressed lung metastasis and tumoral growth	↓mTOR	[62]

Declarations

Author contributions

MG, SR conducted conceptualization; SR, IN, ND, MG wrote original draft preparation; and SR, IN, ND, MG wrote, reviewed, and edited the manuscript. All the authors have read the manuscript and agreed to the published version of the manuscript.

Conflicts of interest

The authors declare that they have no conflict of interest.

Ethical approval

Not Applicable.

Consent to participate

Not Applicable.

Consent to publication

Not Applicable.

Availability of data and materials

Not Applicable.

Funding

This work was supported by the Department of Biotechnology (DBT), under its Ramalingaswami Fellowship number BT/RLF/Re-entry/24/2014 and Science and Engineering Research Board under its ECRA scheme (SERB File No. ECR/2016/001519) award to Dr. Manoj Garg. The sponsor(s) have no role in designing, analysis, interpretation, and writing.

Copyright

References

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. [DOI] [PubMed]

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. [DOI] [PubMed]

GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1659–724. [DOI] [PubMed] [PMC]

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major pattern in GLOBOCAN 2012. Int J Cancer. 2015;36:E359–86. [DOI]

Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4:e609–16. [DOI] [PubMed]

Wong ALA, Hirpara JL, Pervaiz S, Eu JQ, Sethi G, Goh BC. Do STAT3 inhibitors have potential in the future for cancer therapy? Expert Opin Investig Drugs. 2017;26:883–87. [DOI]

Blackadar CB. Historical review of the causes of cancer. World J Clin Oncol. 2016;7:54–86. [DOI] [PubMed] [PMC]

Kirtonia A, Gala K, Fernandes SG, Pandya G, Pandey AK, Sethi G, et al. Repurposing of drugs: an attractive pharmacological strategy for cancer therapeutics. Semin Cancer Biol. 2020;5:S1044–579X(20)30094–8. [DOI]

Shanmugam MK, Warrier S, Kumar AP, Sethi G, Arfuso F. Potential role of natural compounds as anti-angiogenic agents in cancer. Curr Vasc Pharmacol. 2017;15:503–19. [DOI] [PubMed]

10.

Ashrafizadeh M, Javanmardi S, Moradi-Ozarlou M, Mohammadinejad R, Farkhondeh T, Samarghandian S, et al. Natural products and phytochemical nanoformulations targeting mitochondria in oncotherapy: an updated review on resveratrol. Biosci Rep. 2020;40:BSR20200257. [DOI] [PubMed] [PMC]

11.

Patra S, Mishra SR, Behera BP, Mahapatra KK, Panigrahi DP, Bhol CS, et al. Autophagy-modulating phytochemicals in cancer therapeutics: current evidences and future perspectives. Semin Cancer Biol. 2020;22:S1044–579X(20)30104–8. [DOI]

12.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. [DOI] [PubMed]

13.

O’Brien ME, Borthwick A, Rigg A, Leary A, Assersohn L, Last K, et al. Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients. Br J Cancer. 2006;95:1632–36. [DOI] [PubMed] [PMC]

14.

Naz I, Ramchandani S, Khan MR, Yang MH, Ahn KS. Anticancer potential of raddeanin A, a natural triterpenoid isolated from Anemone raddeana Regel. Molecules. 2020;25:1035. [DOI]

15.

Ramchandani S, Naz I, Lee JH, Khan MR, Ahn KS. An overview of the potential antineoplastic effects of casticin. Molecules. 2020;25:1287. [DOI]

16.

Prasannan R, Kalesh KA, Shanmugam MK, Nachiyappan A, Ramachandran L, Nguyen AH, et al. Key cell signaling pathways modulated by zerumbone: role in the prevention and treatment of cancer. Biochem Pharmacol. 2012;4:1268–76. [DOI]

17.

Kong W, Li C, Qi Q, Shen J, Chang K. Cardamonin induces G2/M arrest and apoptosis via activation of the JNK-FOXO3a pathway in breast cancer cells. Cell Biol Int. 2019;[Epub ahead of print]. [DOI]

18.

Nawaz J, Rasul A, Shah MA, Hussain G, Riaz A, Sarfraz I, et al. Cardamonin: a new player to fight cancer via multiple cancer signaling pathways. Life Sci. 2020;250:117591. [DOI] [PubMed]

19.

James S, Aparna JS, Paul AM, Lankadasari MB, Mohammed S, Binu VS, et al. Cardamonin inhibits colonic neoplasia through modulation of MicroRNA expression. Sci Rep. 2017;7:13945. [DOI] [PubMed] [PMC]

20.

Shrivastava S, Jeengar MK, Thummuri D, Koval A, Katanaev VL, Marepally S, et al. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition. Biofactors. 2017;43:152–69. [DOI] [PubMed]

21.

Kashyap D, Tuli HS, Yerer MB, Sharma A, Sak K, Srivastava S, et al. Natural product-based nanoformulations for cancer therapy: opportunities and challenges. Semin Cancer Biol. 2019;[Epub ahead of print]. [DOI]

22.

Merarchi M, Sethi G, Shanmugam MK, Fan L, Arfuso F, Ahn KS. Role of natural products in modulating histone deacetylases in cancer. Molecules. 2019;24:1047. [DOI]

23.

Hardy SD, Shinde A, Wang WH, Wendt MK, Geahlen RL. Regulation of epithelial-mesenchymal transition and metastasis by TGF-β, P-bodies, and autophagy. Oncotarget. 2017;8:103302–14. [DOI] [PubMed] [PMC]

24.

Tewari D, Nabavi SF, Nabavi SM, Sureda A, Farooqi AA, Atanasov AG, et al. Targeting activator protein 1 signaling pathway by bioactive natural agents: possible therapeutic strategy for cancer prevention and intervention. Pharmacol Res. 2018;128:366–75. [DOI] [PubMed]

25.

Yang SF, Weng CJ, Sethi G, Hu DN. Natural bioactives and phytochemicals serve in cancer treatment and prevention. Evid Based Complement Alternat Med. 2013;2013:698190. [DOI] [PubMed] [PMC]

26.

Break MKB, Chiang M, Wiart C, Chin CF, Khoo ASB, Khoo TJ. Cytotoxic activity of Boesenbergia rotunda extracts against nasopharyngeal carcinoma cells (HK1). Cardamonin, a Boesenbergia rotunda constituent, inhibits growth and migration of HK1 cells by inducing caspase-dependent apoptosis and G2/M-phase arrest. Nutr Cancer. 2002;9:1–11. [DOI]

27.

Yarla NS, Bishayee A, Sethi G, Reddanna P, Kalle AM, Dhananjaya BL, et al. Targeting arachidonic acid pathway by natural products for cancer prevention and therapy. Semin Cancer Biol. 2016;40–41:48–81. [DOI]

28.

Nie X, Chen H, Niu P, Zhu Y, Zhou J, Jiang L, et al. DAP1 negatively regulates autophagy induced by cardamonin in SKOV3 cells. Cell Bio Int. 2020;44:2192–201. [DOI] [PubMed]

29.

National Center for Biotechnology Information (2020). PubChem Compound Summary for CID 641785, Cardamonin. Accessed July 7, 2020 from https://pubchem.ncbi.nlm.nih.gov/compound/Cardamonin [DOI]

30.

Gonçalves LM, Valente IM, Rodrigues JA. An overview on cardamonin. J Med Food. 2014;17:633–40. [DOI] [PubMed] [PMC]

31.

Wang C, Kar S, Lai X, Cai W, Arfuso F, Sethi G, et al. Triple negative breast cancer in Asia: an insider’s view. Cancer Treat Rev. 2018;62:29–38. [DOI] [PubMed]

32.

Jia LY, Shanmugam MK, Sethi G, Bishayee A. Potential role of targeted therapies in the treatment of triple-negative breast cancer. Anticancer Drugs. 2016;27:147–55. [DOI] [PubMed]

33.

Kansara S, Pandey V, Lobie PE, Sethi G, Garg M, Pandey AK. Mechanistic involvement of long non-coding RNAs in oncotherapeutics resistance in triple-negative breast cancer. Cells. 2020;9:1511. [DOI]

34.

Liu L, Ahn KS, Shanmugam MK, Wang H, Shen H, Arfuso F, et al. Oleuropein induces apoptosis via abrogating NF-κB activation cascade in estrogen receptor-negative breast cancer cells. J Cell Biochem. 2019;120:4504–13. [DOI] [PubMed]

35.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. [DOI] [PubMed]

36.

Jin J, Qiu S, Wang P, Liang X, Huang F, Wu H, et al. Cardamonin inhibits breast cancer growth by repressing HIF-1α-dependent metabolic reprogramming. J Exp Clin Cancer Res. 2019;38:377. [DOI] [PubMed] [PMC]

37.

Jia D, Tan Y, Liu H, Ooi S, Li L, Wright K, et al. Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo. Oncotarget. 2016;7:771–85. [DOI] [PubMed] [PMC]

38.

Shinde A, Hardy SD, Kim D, Akhand SS, Jolly MK, Wang WH, et al. Spleen tyrosine kinase-mediated autophagy is required for epithelial-mesenchymal plasticity and metastasis in breast cancer. Cancer Res. 2019;79:1831–43. [DOI] [PubMed] [PMC]

39.

Libring S, Shinde A, Chanda MK, Nuru M, George H, Saleh AM, et al. The dynamic relationship of breast cancer cells and fibroblasts in fibronectin accumulation at primary and metastatic tumor sites. Cancers. 2020;12:1270. [DOI]

40.

Ningegowda R, Shivananju NS, Rajendran P, BasappaRangappa KS, Chinnathambi A, et al. A novel 4,6-disubstituted-1,2,4-triazolo-1,3,4-thiadiazole derivative inhibits tumor cell invasion and potentiates the apoptotic effect of TNFα by abrogating NF-κB activation cascade. Apoptosis. 2017;22:145–57. [DOI] [PubMed]

41.

Niu P, Li J, Chen H, Zhu Y, Zhou J, Shi D. Anti-proliferative effect of cardamonin on mTOR inhibitor-resistant cancer cells. Mol Med Rep. 2020;21:1399–407. [DOI] [PubMed]

42.

Lu S, Lin C, Cheng X, Hua H, Xiang T, Huang Y, et al. Cardamonin reduces chemotherapy resistance of colon cancer cells via the TSP50/NF-κB pathway in vitro. Oncol Lett. 2018;15:9641–6. [DOI] [PubMed] [PMC]

43.

Park S, Gwak J, Han SJ, Oh S. Cardamonin suppresses the proliferation of colon cancer cells by promoting β-catenin degradation. Biol Pharm Bull. 2013;36:1040–4. [DOI] [PubMed]

44.

Manu KA, Shanmugam MK, Ramachandran L, Li F, Siveen KS, Chinnathambi A, et al. Isorhamnetin augments the anti-tumor effect of capecitabine through the negative regulation of NF-κB signaling cascade in gastric cancer. Cancer Lett. 2015;363:28–36. [DOI] [PubMed]

45.

Manu KA, Shanmugam MK, Li F, Chen L, Siveen KS, Ahn KS, et al. Simvastatin sensitizes human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factor-kappa B-regulated gene products. J Mol Med (Berl). 2014;92:267–76. [DOI] [PubMed]

46.

Manu KA, Shanmugam MK, Ramachandran L, Li F, Fong CW, Kumar AP, et al. First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway. Clin Cancer Res. 2012;18:2220–9. [DOI] [PubMed]

47.

Hwang ST, Kim C, Lee JH, Chinnathambi A, Alharbi SA, Shair OHM, et al. Cycloastragenol can negate constitutive STAT3 activation and promote paclitaxel-induced apoptosis in human gastric cancer cells. Phytomedicine. 2019;59:152907. [DOI] [PubMed]

48.

Xu Z, Chen L, Xiao Z, Zhu Y, Jiang H, Jin Y, et al. Potentiation of the anticancer effect of doxorubicinin drug-resistant gastric cancer cells by tanshinone IIA. Phytomedicine. 2018;51:58–67. [DOI] [PubMed]

49.

Wang Z, Tang X, Wu X, Yang M, Wang W, Wang L, et al. Cardamonin exerts anti-gastric cancer activity via inhibiting LncRNA-PVT1-STAT3 axis. Biosci Rep. 2019;39:BSR20190357. [DOI] [PubMed] [PMC]

50.

Hou G, Yuan X, Li Y, Hou G, Liu X. Cardamonin, a natural chalcone, reduces 5-fluorouracil resistance of gastric cancer cells through targeting Wnt/β-catenin signal pathway. Invest New Drugs. 2020;38:329–39. [DOI] [PubMed]

51.

Shabnam B, Padmavathi G, Banik K, Girisa S, Monisha J, Sethi G, et al. Sorcin a potential molecular target for cancer therapy. Transl Oncol. 2018;11:1379–89. [DOI] [PubMed] [PMC]

52.

Wu N, Liu J, Zhao X, Yan Z, Jiang B, Wang L, et al. Cardamonin induces apoptosis by suppressing STAT3 signaling pathway in glioblastoma stem cells. Tumour Biol. 2015;36:9667–76. [DOI] [PubMed]

53.

Liao NC, Shih YL, Chou JS, Chen KW, Chen YL, Lee MH, et al. Cardamonin induces cell cycle arrest, apoptosis and alters apoptosis associated gene expression in WEHI-3 mouse leukemia cells. Am J Chin Med. 2019;47:635–56. [DOI] [PubMed]

54.

Wang L, Syn NL, Subhash VV, Any Y, Thuya WL, Cheow ESH, et al. Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling. Cancer Lett. 2018;417:152–60. [DOI] [PubMed]

55.

Struzik J, Szulc-Dąbrowska L. NF-κB signaling in targeting tumor cells by oncolytic viruses-therapeutic perspectives. Cancers (Basel). 2018;10:426. [DOI]

56.

Lee JH, Mohan CD, Basappa S, Rangappa S, Chinnathambi A, Alahmadi TA, et al. The IκB kinase inhibitor ACHP targets the STAT3 signaling pathway in human non-small cell lung carcinoma cells. Biomolecules. 2019;9:875. [DOI]

57.

Hayano T, Garg M, Yin D, Sudo M, Kawamata N, Shi S, et al. SOX7 is down-regulated in lung cancer. J Exp Clin Cancer Res. 2013;32:17. [DOI] [PubMed] [PMC]

58.

Baek SH, Ko JH, Lee JH, Kim C, Lee H, Nam D, et al. Ginkgolic acid inhibits invasion and migration and TGF-β-induced EMT of lung cancer cells through PI3K/Akt/mTOR inactivation. J Cell Physiol. 2017;232:346–54. [DOI] [PubMed]

59.

Ong PS, Wang L, Chia DM, Seah JY, Kong LR, Thuya WL, et al. A novel combinatorial strategy using Seliciclib® and Belinostat® for eradication of non-small cell lung cancer via apoptosis induction and BID activation. Cancer Lett. 2016;381:49–57. [DOI] [PubMed]

60.

Zhou X, Zhou R, Li Q, Jie X, Hong J, Zong Y, et al. Cardamonin inhibits the proliferation and metastasis of non-small-cell lung cancer cells by suppressing the PI3K/Akt/mTOR pathway. Anticancer Drugs. 2019;30:241–50. [DOI] [PubMed]

61.

Yue Y, Liu L, Liu P, Li Y, Lu H, Li Y, et al. Cardamonin as a potential treatment for melanoma induces human melanoma cell apoptosis. Oncol Lett. 2020;19:1393–9. [DOI] [PubMed] [PMC]

62.

He W, Jiang Y, Zhang X, Zhang Y, Ji H, Zhang N. Anticancer cardamonin analogs suppress the activation of NF-kappaB pathway in lung cancer cells. Mol Cell Biochem. 2014;389:25–33. [DOI] [PubMed]

63.

Uzunalli G, Dieterly AM, Kemet CM, Weng HY, Soepriatna AH, Goergen CJ, et al. Dynamic transition of the blood-brain barrier in the development of non-small cell lung cancer brain metastases. Oncotarget. 2019;10:6334–48. [DOI] [PubMed] [PMC]

64.

Tang Y, Fang Q, Shi D, Niu P, Chen Y, Deng J. mTOR inhibition of cardamonin on antiproliferation of A549 cells is involved in a FKBP12 independent fashion. Life Sci. 2014;99:44–51. [DOI] [PubMed]

65.

Berning L, Scharf L, Aplak E, Stucki D, von Montfort C, Reichert AS, et al. In vitro selective cytotoxicity of the dietary chalcone cardamonin (CD) on melanoma compared to healthy cells is mediated by apoptosis. PLoS One. 2019;14:e0222267. [DOI] [PubMed] [PMC]

66.

Kim C, Lee JH, Ko JH, Chinnathambi A, Alharbi SA, Shair OHM, et al. Formononetin regulates multiple oncogenic signaling cascades and enhances sensitivity to bortezomib in a multiple myeloma mouse model. Biomolecules. 2019;9:262. [DOI]

67.

Kim C, Lee SG, Yang WM, Arfuso F, Um JY, Kumar AP, et al. Formononetin-induced oxidative stress abrogates the activation of STAT3/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model. Cancer Lett. 2018;431:123–41. [DOI] [PubMed]

68.

Shanmugam MK, Ahn KS, Lee JH, Kannaiyan R, Mustafa N, Manu KA, et al. Celastrol attenuates the invasion and migration and augments the anticancer effects of bortezomib in a xenograft mouse model of multiple myeloma. Front Pharmacol. 2018;9:365. [DOI] [PubMed] [PMC]

69.

Kim SM, Lee JH, Sethi G, Kim C, Baek SH, Nam D, et al. Bergamottin, a natural furanocoumarin obtained from grapefruit juice induces chemosensitization and apoptosis through the inhibition of STAT3 signaling pathway in tumor cells. Cancer Lett. 2014;354:153–63. [DOI] [PubMed]

70.

Wang J, Qiu R, Yuan L, Meng F, Tang Q. Analysis on the Alpinia katsumadai components of Zingiberaceae plants and their functions on myeloma resistance. Pak J Pharm Sci. 2015;28 Suppl 3:1065–8. [PubMed]

71.

Qin Y, Sun CY, Lu FR, Shu XR, Yang D, Chen L, et al. Cardamonin exerts potent activity against multiple myeloma through blockade of NF-κB pathway in vitro. Leuk Res. 2012;36:514–20. [DOI] [PubMed]

72.

Niu P, Shi D, Zhang S, Zhu Y, Zhou J. Cardamonin enhances the anti-proliferative effect of cisplatin on ovarian cancer. Oncology Lett. 2018;15:3991–97. [DOI]

73.

Shi D, Zhao D, Niu P, Zhu Y, Zhou J, Chen H. Glycolysis inhibition via mTOR suppression is a key step in cardamonin-induced autophagy in SKOV3 cells. BMC Complement Altern Med. 2018;18:317. [DOI] [PubMed] [PMC]

74.

Zhang J, Sikka S, Siveen KS, Lee JH, Um JY, Kumar AP, et al. Cardamonin represses proliferation, invasion, and causes apoptosis through the modulation of signal transducer and activator of transcription 3 pathway in prostate cancer. Apoptosis. 2017;22:158–68. [DOI] [PubMed]

75.

Pascoal AC, Ehrenfried CA, Lopez BG, de Araujo TM, Pascoal VD, Gilioli R, et al. Antiproliferative activity and induction of apoptosis in PC-3 cells by the chalcone cardamonin from Campomanesia adamantium (Myrtaceae) in a bioactivity-guided study. Molecules. 2014;19:1843–55. [DOI] [PubMed] [PMC]

76.

Okoniewska K, Konieczny MT, Lemke K, Grabowski T. Pharmacokinetics studies of oxathio-heterocycle fused chalcones. Eur J Drug Metab Pharmacokinet. 2017;42:49–58. [DOI] [PubMed]

77.

Gutteridge CE, Thota DS, Curtis SM, Kozar MP, Li Q, Xie L, et al. In vitro biotransformation, in vivo efficacy and pharmacokinetics of antimalarial chalcones. Pharmacology. 2011;87:96–104. [DOI] [PubMed]

78.

Jaiswal S, Shukla M, Sharma A, Rangaraj N, Vaghasiya K, Malik MY, et al. Preclinical pharmacokinetics and ADME characterization of a novel anticancer chalcone, cardamonin. Drug Test Anal. 2016;9:1124–36. [DOI] [PubMed]

79.

Jaiswal S, Sharma A, Shukla M, Lal J. Gender-related pharmacokinetics and bioavailability of a novel anticancer chalcone, cardamonin, in rats determined by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;986–987:23–30. [DOI]